secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001104659-23-098809
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aziyo Biologics rebrands as Elutia; shifts to drug-eluting biomatrices; ticker now ELUT
--------------------------------------------------------------------------------

- Name change to Elutia Inc. effective Sept 6, 2023; ticker switches from AZYO to ELUT on Nasdaq on Sept 7.
- Rebranding reflects strategic focus on drug-eluting biomatrix (DEB) technology to improve surgical outcomes.
- First DEB product CanGaroo RM for pacemaker/defibrillator market expected to launch next year; market valued at $600M.
- Developing SimpliDerm RM for breast reconstruction ($500M market) to address post-op infection rates exceeding 10%.
- CEO Randy Mills highlights commitment to DEB technology; no immediate financial impact or guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/0001104659-23-098809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/tm2325574d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-098809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer